| Year |
Citation |
Score |
| 2022 |
Abram M, Jakubiec M, Reeb K, Cheng MH, Gedschold R, Rapacz A, Mogilski S, Socała K, Nieoczym D, Szafarz M, Latacz G, Szulczyk B, Kalinowska-Tłuścik J, Gawel K, Esguerra CV, et al. Discovery of ()--Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [], a Novel Orally Bioavailable EAAT2 Modulator with Drug-like Properties and Potent Antiseizure Activity . Journal of Medicinal Chemistry. PMID 35984707 DOI: 10.1021/acs.jmedchem.2c00534 |
0.309 |
|
| 2022 |
Jakubiec M, Abram M, Zagaja M, Andres-Mach M, Szewczyk A, Latacz G, Szulczyk B, Socała K, Nieoczym D, Wlaź P, Metcalf CS, Wilcox K, Kamiński RM, Kamiński K. New Phenylglycinamide Derivatives with Hybrid Structure as Candidates for New Broad-Spectrum Anticonvulsants. Cells. 11. PMID 35740990 DOI: 10.3390/cells11121862 |
0.311 |
|
| 2022 |
Zhang Y, Heylen L, Partoens M, Mills JD, Kaminski RM, Godard P, Gillard M, de Witte PAM, Siekierska A. Connectivity Mapping Using a Novel Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery. Frontiers in Molecular Neuroscience. 15: 881933. PMID 35686059 DOI: 10.3389/fnmol.2022.881933 |
0.365 |
|
| 2021 |
Abram M, Jakubiec M, Rapacz A, Mogilski S, Latacz G, Szulczyk B, Szafarz M, Socała K, Nieoczym D, Wyska E, Wlaź P, Kamiński RM, Kamiński K. Identification of New Compounds with Anticonvulsant and Antinociceptive Properties in a Group of 3-substituted (2,5-dioxo-pyrrolidin-1-yl)(phenyl)-Acetamides. International Journal of Molecular Sciences. 22. PMID 34884898 DOI: 10.3390/ijms222313092 |
0.328 |
|
| 2021 |
Lovisari F, Roncon P, Soukoupova M, Paolone G, Labasque M, Ingusci S, Falcicchia C, Marino P, Johnson M, Rossetti T, Petretto E, Leclercq K, Kaminski RM, Moyon B, Webster Z, et al. Implication of sestrin3 in epilepsy and its comorbidities. Brain Communications. 3: fcaa130. PMID 33758823 DOI: 10.1093/braincomms/fcaa130 |
0.331 |
|
| 2020 |
Muglia P, Hannestad J, Brandt C, DeBruyn S, Germani M, Lacroix B, Majoie M, Otoul C, Sciberras D, Steinhoff BJ, Van Laere K, Van Paesschen W, Webster E, Kaminski RM, Werhahn KJ, et al. Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach. Brain Communications. 2: fcaa183. PMID 33241213 DOI: 10.1093/braincomms/fcaa183 |
0.363 |
|
| 2020 |
Abram M, Jakubiec M, Rapacz A, Mogilski S, Latacz G, Kamiński RM, Kamiński K. The Search for New Anticonvulsants in a Group of (2,5-Dioxopyrrolidin-1-yl)(phenyl)Acetamides with Hybrid Structure-Synthesis and In Vivo/In Vitro Studies. International Journal of Molecular Sciences. 21. PMID 33233618 DOI: 10.3390/ijms21228780 |
0.32 |
|
| 2020 |
Abram M, Rapacz A, Mogilski S, Latacz G, Lubelska A, Kamiński RM, Kamiński K. Multitargeted Compounds Derived from (2,5-Dioxopyrrolidin-1-yl)(phenyl)-Acetamides as Candidates for Effective Anticonvulsant and Antinociceptive Agents. Acs Chemical Neuroscience. PMID 32479058 DOI: 10.1021/acschemneuro.0c00257 |
0.356 |
|
| 2020 |
Niespodziany I, Ghisdal P, Mullier B, Wood M, Provins L, Kaminski RM, Wolff C. Functional characterization of the antiepileptic drug candidate, padsevonil, on GABA receptors. Epilepsia. PMID 32297665 DOI: 10.1111/epi.16497 |
0.331 |
|
| 2020 |
Klein P, Friedman A, Hameed MQ, Kaminski RM, Bar-Klein G, Klitgaard H, Koepp M, Jozwiak S, Prince DA, Rotenberg A, Twyman R, Vezzani A, Wong M, Löscher W. Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? Epilepsia. 61: 359-386. PMID 32196665 DOI: 10.1111/Epi.16450 |
0.392 |
|
| 2020 |
Auvin S, Dozières-Puyravel B, Avbersek A, Sciberras D, Collier J, Leclercq K, Mares P, Kaminski RM, Muglia P. Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome. Annals of Clinical and Translational Neurology. PMID 32106360 DOI: 10.1002/acn3.50998 |
0.393 |
|
| 2019 |
Johnson MR, Kaminski RM. A systems-level framework for anti-epilepsy drug discovery. Neuropharmacology. 107868. PMID 31785261 DOI: 10.1016/j.neuropharm.2019.107868 |
0.451 |
|
| 2019 |
Auvin S, Avbersek A, Bast T, Chiron C, Guerrini R, Kaminski RM, Lagae L, Muglia P, Cross JH. Drug Development for Rare Paediatric Epilepsies: Current State and Future Directions. Drugs. PMID 31734883 DOI: 10.1007/s40265-019-01223-9 |
0.394 |
|
| 2019 |
Wood M, Daniels V, Provins L, Wolff C, Kaminski RM, Gillard M. Pharmacological profile of the novel antiepileptic drug candidate padsevonil - interactions with synaptic vesicle 2 proteins and the GABAA receptor. The Journal of Pharmacology and Experimental Therapeutics. PMID 31619465 DOI: 10.1124/jpet.119.261149 |
0.356 |
|
| 2019 |
Leclercq K, Matagne A, Provins L, Klitgaard H, Kaminski RM. Pharmacological profile of the antiepileptic drug candidate padsevonil - characterization in rodent seizure and epilepsy models. The Journal of Pharmacology and Experimental Therapeutics. PMID 31619464 DOI: 10.1124/jpet.119.261222 |
0.552 |
|
| 2019 |
Leclercq K, Liefferinge JV, Albertini G, Neveux M, Dardenne S, Mairet-Coello G, Vandenplas C, Deprez T, Chong SA, Foerch P, Bentea E, Sato H, Maher P, Massie A, Smolders I, ... Kaminski RM, et al. Anticonvulsant and antiepileptogenic effects of system inactivation in chronic epilepsy models. Epilepsia. PMID 31179549 DOI: 10.1111/epi.16055 |
0.495 |
|
| 2018 |
Frigerio F, Pasqualini G, Craparotta I, Marchini S, van Vliet EA, Foerch P, Vandenplas C, Leclercq K, Aronica E, Porcu L, Pistorius K, Colas RA, Hansen TV, Perretti M, Kaminski RM, et al. n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. Brain : a Journal of Neurology. PMID 30307467 DOI: 10.1093/brain/awy247 |
0.435 |
|
| 2018 |
Srivastava PK, Eyll JV, Godard P, Mazzuferi M, Delahaye-Duriez A, Steenwinckel JV, Gressens P, Danis B, Vandenplas C, Foerch P, Leclercq K, Mairet-Coello G, Cardenas A, Vanclef F, Laaniste L, ... ... Kaminski RM, et al. A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. Nature Communications. 9: 3561. PMID 30177815 DOI: 10.1038/s41467-018-06008-4 |
0.429 |
|
| 2017 |
Klein P, Dingledine R, Aronica E, Bernard C, Blümcke I, Boison D, Brodie MJ, Brooks-Kayal AR, Engel J, Forcelli PA, Hirsch LJ, Kaminski RM, Klitgaard H, Kobow K, Lowenstein DH, et al. Commonalities in epileptogenic processes from different acute brain insults: Do they translate? Epilepsia. PMID 29247482 DOI: 10.1111/Epi.13965 |
0.618 |
|
| 2017 |
Zhang Y, Vanmeert M, Siekierska A, Ny A, John J, Callewaert G, Lescrinier E, Dehaen W, de Witte PAM, Kaminski RM. Inhibition of glutamate decarboxylase (GAD) by ethyl ketopentenoate (EKP) induces treatment-resistant epileptic seizures in zebrafish. Scientific Reports. 7: 7195. PMID 28775328 DOI: 10.1038/s41598-017-06294-w |
0.42 |
|
| 2017 |
Aronica E, Bauer S, Bozzi Y, Caleo M, Dingledine R, Gorter JA, Henshall DC, Kaufer D, Koh S, Löscher W, Louboutin JP, Mishto M, Norwood BA, Palma E, Poulter MO, ... ... Kaminski RM, et al. Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia. 58: 27-38. PMID 28675563 DOI: 10.1111/Epi.13783 |
0.432 |
|
| 2017 |
Mullier B, Wolff C, Sands ZA, Ghisdal P, Muglia P, Kaminski RM, André VM. GRIN2B gain of function mutations are sensitive to radiprodil, a negative allosteric modulator of GluN2B-containing NMDA receptors. Neuropharmacology. PMID 28533163 DOI: 10.1016/J.Neuropharm.2017.05.017 |
0.339 |
|
| 2017 |
Srivastava PK, Bagnati M, Delahaye-Duriez A, Ko JH, Rotival M, Langley SR, Shkura K, Mazzuferi M, Danis B, van Eyll J, Foerch P, Behmoaras J, Kaminski RM, Petretto E, Johnson MR. Genome-wide analysis of differential RNA editing in epilepsy. Genome Research. 27: 440-450. PMID 28250018 DOI: 10.1101/gr.210740.116 |
0.378 |
|
| 2017 |
Tamir S, Cochran S, Argueta C, Lee M, Shacham S, Leclerq K, Kaminski R, Ryck MD, Kenda B. KPT-350, a selective inhibitor of nuclear export (SINE) compound, shows efficacy in the mouse pilocapine model of temporal lobe epilepsy Journal of the Neurological Sciences. 381: 87-88. DOI: 10.1016/J.Jns.2017.08.294 |
0.39 |
|
| 2016 |
Delahaye-Duriez A, Srivastava P, Shkura K, Langley SR, Laaniste L, Moreno-Moral A, Danis B, Mazzuferi M, Foerch P, Gazina EV, Richards K, Petrou S, Kaminski RM, Petretto E, Johnson MR. Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery. Genome Biology. 17: 245. PMID 27955713 DOI: 10.1186/s13059-016-1097-7 |
0.42 |
|
| 2016 |
Surges R, Kretschmann A, Abnaof K, van Rikxoort M, Ridder K, Fröhlich H, Danis B, Kaminski RM, Foerch P, Elger CE, Weinsberg F, Pfeifer A. Changes in serum miRNAs following generalized convulsive seizures in human mesial temporal lobe epilepsy. Biochemical and Biophysical Research Communications. PMID 27833019 DOI: 10.1016/J.Bbrc.2016.11.029 |
0.35 |
|
| 2016 |
Löscher W, Gillard M, Sands ZA, Kaminski RM, Klitgaard H. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. Cns Drugs. PMID 27752944 DOI: 10.1007/s40263-016-0384-x |
0.481 |
|
| 2016 |
Tomaciello F, Leclercq K, Kaminski RM. Resveratrol lacks protective activity against acute seizures in mouse models. Neuroscience Letters. PMID 27600732 DOI: 10.1016/j.neulet.2016.09.002 |
0.52 |
|
| 2016 |
Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 57: 538-48. PMID 26920914 DOI: 10.1111/epi.13340 |
0.507 |
|
| 2015 |
Lidster K, Jefferys JG, Blümcke I, Crunelli V, Flecknell P, Frenguelli BG, Gray WP, Kaminski R, Pitkänen A, Ragan I, Shah M, Simonato M, Trevelyan A, Volk H, Walker M, et al. Opportunities for improving animal welfare in rodent models of epilepsy and seizures. Journal of Neuroscience Methods. PMID 26376175 DOI: 10.1016/J.Jneumeth.2015.09.007 |
0.467 |
|
| 2015 |
Leclercq K, Kaminski RM. Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. Epilepsy & Behavior : E&B. 49: 55-60. PMID 26123104 DOI: 10.1016/j.yebeh.2015.06.011 |
0.468 |
|
| 2015 |
Leclercq K, Afrikanova T, Langlois M, De Prins A, Buenafe OE, Rospo CC, Van Eeckhaut A, de Witte PA, Crawford AD, Smolders I, Esguerra CV, Kaminski RM. Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish. Epilepsy & Behavior : E&B. 45: 53-63. PMID 25845493 DOI: 10.1016/j.yebeh.2015.03.019 |
0.51 |
|
| 2015 |
Leclercq K, Kaminski RM. Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model. Epilepsia. 56: 310-8. PMID 25524462 DOI: 10.1111/epi.12893 |
0.484 |
|
| 2015 |
Kretschmann A, Danis B, Andonovic L, Abnaof K, van Rikxoort M, Siegel F, Mazzuferi M, Godard P, Hanon E, Fröhlich H, Kaminski RM, Foerch P, Pfeifer A. Different microRNA profiles in chronic epilepsy versus acute seizure mouse models. Journal of Molecular Neuroscience : Mn. 55: 466-79. PMID 25078263 DOI: 10.1007/s12031-014-0368-6 |
0.42 |
|
| 2015 |
Leclercq K, Kaminski RM. Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model Epilepsy and Behavior. DOI: 10.1016/j.yebeh.2015.06.011 |
0.405 |
|
| 2014 |
Fritsch B, Reis J, Gasior M, Kaminski RM, Rogawski MA. Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 5765-75. PMID 24760837 DOI: 10.1523/Jneurosci.5307-13.2014 |
0.734 |
|
| 2014 |
Kaminski RM, Rogawski MA, Klitgaard H. The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 385-400. PMID 24671870 DOI: 10.1007/s13311-014-0266-1 |
0.623 |
|
| 2014 |
Leclercq K, Matagne A, Kaminski RM. Low potency and limited efficacy of antiepileptic drugs in the mouse 6 Hz corneal kindling model. Epilepsy Research. 108: 675-83. PMID 24661426 DOI: 10.1016/j.eplepsyres.2014.02.013 |
0.483 |
|
| 2013 |
Pitkänen A, Nehlig A, Brooks-Kayal AR, Dudek FE, Friedman D, Galanopoulou AS, Jensen FE, Kaminski RM, Kapur J, Klitgaard H, Löscher W, Mody I, Schmidt D. Issues related to development of antiepileptogenic therapies. Epilepsia. 54: 35-43. PMID 23909852 DOI: 10.1111/Epi.12297 |
0.318 |
|
| 2013 |
Mazzuferi M, Kumar G, van Eyll J, Danis B, Foerch P, Kaminski RM. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. Annals of Neurology. 74: 560-8. PMID 23686862 DOI: 10.1002/ana.23940 |
0.442 |
|
| 2012 |
Mazzuferi M, Kumar G, Rospo C, Kaminski RM. Rapid epileptogenesis in the mouse pilocarpine model: video-EEG, pharmacokinetic and histopathological characterization. Experimental Neurology. 238: 156-67. PMID 22960187 DOI: 10.1016/j.expneurol.2012.08.022 |
0.492 |
|
| 2012 |
Simonato M, Löscher W, Cole AJ, Dudek FE, Engel J, Kaminski RM, Loeb JA, Scharfman H, Staley KJ, Velíšek L, Klitgaard H. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia. 53: 1860-7. PMID 22708847 DOI: 10.1111/J.1528-1167.2012.03541.X |
0.383 |
|
| 2012 |
Baruah PK, Dinsmore J, King AM, Salomé C, De Ryck M, Kaminski R, Provins L, Kohn H. Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides. Bioorganic & Medicinal Chemistry. 20: 3551-64. PMID 22546207 DOI: 10.1016/J.Bmc.2012.04.002 |
0.356 |
|
| 2012 |
Barkmeier DT, Senador D, Leclercq K, Pai D, Hua J, Boutros NN, Kaminski RM, Loeb JA. Electrical, molecular and behavioral effects of interictal spiking in the rat. Neurobiology of Disease. 47: 92-101. PMID 22472188 DOI: 10.1016/J.Nbd.2012.03.026 |
0.437 |
|
| 2011 |
King AM, De Ryck M, Kaminski R, Valade A, Stables JP, Kohn H. Defining the structural parameters that confer anticonvulsant activity by the site-by-site modification of (R)-N'-benzyl 2-amino-3-methylbutanamide. Journal of Medicinal Chemistry. 54: 6432-42. PMID 21861466 DOI: 10.1021/Jm200760A |
0.302 |
|
| 2011 |
King AM, Salomé C, Dinsmore J, Salomé-Grosjean E, De Ryck M, Kaminski R, Valade A, Kohn H. Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities. Journal of Medicinal Chemistry. 54: 4815-30. PMID 21639114 DOI: 10.1021/Jm2004305 |
0.316 |
|
| 2011 |
Kaminski RM, Rogawski MA. 11β-Hydroxylase inhibitors protect against seizures in mice by increasing endogenous neurosteroid synthesis. Neuropharmacology. 61: 133-7. PMID 21458468 DOI: 10.1016/j.neuropharm.2011.03.019 |
0.622 |
|
| 2011 |
Kaminski RM, Fu Z, Venkatesan K, Mazzuferi M, Leclercq K, Seutin V, Vicini S. 11-Deoxycortisol impedes GABAergic neurotransmission and induces drug-resistant status epilepticus in mice. Neuropharmacology. 60: 1098-108. PMID 20883706 DOI: 10.1016/J.Neuropharm.2010.09.021 |
0.549 |
|
| 2011 |
Dekundy A, Kaminski RM. Central Mechanisms of Seizures and Lethality Following Anticholinesterase Pesticide Exposure Anticholinesterase Pesticides: Metabolism, Neurotoxicity, and Epidemiology. 149-164. DOI: 10.1002/9780470640500.ch12 |
0.319 |
|
| 2010 |
Detrait ER, Leclercq K, Löscher W, Potschka H, Niespodziany I, Hanon E, Kaminski RM, Matagne A, Lamberty Y. Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats. Epilepsy Research. 91: 74-83. PMID 20678901 DOI: 10.1016/j.eplepsyres.2010.06.014 |
0.361 |
|
| 2010 |
Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs Epilepsia. 51: 83. DOI: 10.1111/j.1528-1167.2010.02869.x |
0.356 |
|
| 2009 |
Runyon SP, Orr M, Navarro HA, Kepler JA, Rogawski MA, Kaminski RM, Cook CE. 17beta-Nitro-5alpha-androstan-3alpha-ol and its 3beta-methyl derivative: neurosteroid analogs with potent anticonvulsant and anxiolytic activities. European Journal of Pharmacology. 617: 68-73. PMID 19577558 DOI: 10.1016/J.Ejphar.2009.06.052 |
0.542 |
|
| 2009 |
Kaminski RM, Gillard M, Leclercq K, Hanon E, Lorent G, Dassesse D, Matagne A, Klitgaard H. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia. 50: 1729-40. PMID 19486357 DOI: 10.1111/j.1528-1167.2009.02089.x |
0.503 |
|
| 2009 |
Kaminski RM, Matagne A, Patsalos PN, Klitgaard H. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia. 50: 387-97. PMID 18627416 DOI: 10.1111/j.1528-1167.2008.01713.x |
0.466 |
|
| 2008 |
Margineanu DG, Matagne A, Kaminski RM, Klitgaard H. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. Brain Research Bulletin. 77: 282-5. PMID 18722515 DOI: 10.1016/j.brainresbull.2008.07.006 |
0.36 |
|
| 2008 |
Witkin JM, Levant B, Zapata A, Kaminski R, Gasior M. The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors. The Journal of Pharmacology and Experimental Therapeutics. 326: 930-8. PMID 18566292 DOI: 10.1124/jpet.108.139212 |
0.369 |
|
| 2008 |
Kaminski RM, Matagne A, Leclercq K, Gillard M, Michel P, Kenda B, Talaga P, Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology. 54: 715-20. PMID 18207204 DOI: 10.1016/j.neuropharm.2007.11.021 |
0.474 |
|
| 2007 |
Dekundy A, Kaminski RM, Zielinska E, Turski WA. NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice. Toxicology and Applied Pharmacology. 219: 114-21. PMID 17157343 DOI: 10.1016/j.taap.2006.10.030 |
0.489 |
|
| 2007 |
Kaminski RM, Witkin JM, Shippenberg TS. Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. Neuropharmacology. 52: 895-903. PMID 17126860 DOI: 10.1016/J.Neuropharm.2006.10.007 |
0.32 |
|
| 2007 |
Kaminski RM, Blaszczak P, Dekundy A, Parada-Turska J, Calderazzo L, Cavalheiro EA, Turski WA. Lithium-methomyl induced seizures in rats: a new model of status epilepticus? Toxicology and Applied Pharmacology. 219: 122-7. PMID 17092527 DOI: 10.1016/j.taap.2006.09.017 |
0.459 |
|
| 2007 |
Kaminski RM, Henley JM. Wrestling with epilepsy; potential roles for kainate receptor SUMOylation in regulating neuronal excitability Future Neurology. 2: 591-595. DOI: 10.2217/14796708.2.6.591 |
0.334 |
|
| 2007 |
KAMINSKI R, RUNYON S, MARINI H, ROGAWSKI M. Poster Abstract #7: Anticonvulsant Effects of a Synthetic Progestin, Norethindrone, But Not Its A-Ring Reduced Metabolite in Mice Neurotherapeutics. 4: 727-727. DOI: 10.1016/J.NURT.2007.03.011 |
0.451 |
|
| 2006 |
Kaminski RM, Marini H, Ortinski PI, Vicini S, Rogawski MA. The pheromone androstenol (5 alpha-androst-16-en-3 alpha-ol) is a neurosteroid positive modulator of GABAA receptors. The Journal of Pharmacology and Experimental Therapeutics. 317: 694-703. PMID 16415088 DOI: 10.1124/Jpet.105.098319 |
0.569 |
|
| 2006 |
KAMINSKI R, MARINI H, ORTINSKI P, YONEKAWA W, VICINI S, ROGAWSKI M. Androstenol (5α-androst-16-en-3α-ol) Is a Novel Neurosteroid Positive Modulator of GABAA Receptors: In Vitro and In Vivo Studies Neurorx. 3: 413-414. DOI: 10.1016/J.Nurx.2006.05.030 |
0.58 |
|
| 2005 |
Kaminski RM, Marini H, Kim WJ, Rogawski MA. Anticonvulsant activity of androsterone and etiocholanolone. Epilepsia. 46: 819-27. PMID 15946323 DOI: 10.1111/j.1528-1167.2005.00705.x |
0.542 |
|
| 2005 |
Kaminski RM, Shippenberg TS, Witkin JM, Rocha BA. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neuroscience Letters. 382: 51-5. PMID 15911120 DOI: 10.1016/J.Neulet.2005.02.056 |
0.366 |
|
| 2004 |
Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 46: 1097-1104. PMID 32585782 DOI: 10.1016/j.neuropharm.2004.02.010 |
0.634 |
|
| 2004 |
Kaminski RM, Tochman AM, Dekundy A, Turski WA, Czuczwar SJ. Ethosuximide and valproate display high efficacy against lindane-induced seizures in mice. Toxicology Letters. 154: 55-60. PMID 15475178 DOI: 10.1016/j.toxlet.2004.07.002 |
0.545 |
|
| 2004 |
Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia. 45: 864-7. PMID 15230714 DOI: 10.1111/j.0013-9580.2004.04504.x |
0.655 |
|
| 2004 |
Kaminski RM, Banerjee M, Rogawski MA. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology. 46: 1097-104. PMID 15111016 DOI: 10.1016/j.neuropharm.2004.02.010 |
0.664 |
|
| 2004 |
Gasior M, Kaminski R, Witkin JM. Pharmacological modulation of GABA(B) receptors affects cocaine-induced seizures in mice. Psychopharmacology. 174: 211-9. PMID 14985936 DOI: 10.1007/s00213-003-1743-0 |
0.461 |
|
| 2003 |
Kaminski RM, Gasior M, Carter RB, Witkin JM. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. European Journal of Pharmacology. 474: 217-22. PMID 12921865 DOI: 10.1016/S0014-2999(03)02086-7 |
0.367 |
|
| 2003 |
Dekundy A, Kaminski RM, Turski WA. Dizocilpine improves beneficial effects of cholinergic antagonists in anticholinesterase-treated mice. Toxicological Sciences : An Official Journal of the Society of Toxicology. 72: 289-95. PMID 12660363 DOI: 10.1093/toxsci/kfg013 |
0.493 |
|
| 2001 |
Dekundy A, Blaszczak P, Kaminski R, Turski WA. On the interactions between antimuscarinic atropine and NMDA receptor antagonists in anticholinesterase-treated mice Archives of Toxicology. 74: 702-708. PMID 11218047 DOI: 10.1007/s002040000189 |
0.495 |
|
| 2000 |
Tochman AM, Kamiński R, Turski WA, Czuczwar SJ. Protection by conventional and new antiepileptic drugs against lindane-induced seizures and lethal effects in mice Neurotoxicity Research. 2: 63-70. PMID 15545007 DOI: 10.1007/Bf03033328 |
0.511 |
|
| 1999 |
Kaminski R, Jasinski M, Jagiello-Wojtowicz E, Kleinrok Z, Czuczwar SJ. Effect of amlodipine upon the protective activity of antiepileptic drugs against maximal electroshock-induced seizures in mice Pharmacological Research. 40: 319-325. PMID 10527643 DOI: 10.1006/phrs.1999.0518 |
0.417 |
|
| 1998 |
Kozicka M, Kaminski R, Parada-Turska J, Dziki M, Kleinrok Z, Turski WA, Czuczwar SJ. Non-steroidal anti-inflammatory drugs and the protective activity of valproate and diphenylhydantoin against maximal electroshock-induced seizures in mice - An interaction Polish Journal of Pharmacology. 50: 94-95. PMID 9662751 |
0.349 |
|
| 1998 |
Kaminski R, Kozicka M, Parada-turska J, Dziki M, Kleinrok Z, Turski WA, Czuczwar SJ. Effect Of Non-Steroidal Anti-Inflammatory Drugs On The Anticonvulsive Activity Of Valproate And Diphenylhydantoin Against Maximal Electroshock-Induced Seizures In Mice Pharmacological Research. 37: 375-381. PMID 9642033 DOI: 10.1006/Phrs.1998.0309 |
0.411 |
|
| 1998 |
Kamiński R, Wolińska E, Gasior M, Kleinrok Z, Czuczwar SJ. NMDA receptor glycine site antagonist (indole-2-carboxylic acid) enhances the anticonvulsive activity of antiepileptic drugs Neuroscience Research Communications. 22: 137-145. DOI: 10.1002/(SICI)1520-6769(199805/06)22:3<137::AID-NRC2>3.0.CO;2-W |
0.371 |
|
| 1997 |
Kamiński R, Mazurek M, Jasiński M, Kleinrok Z, Czuezwa SJ. P.6.025 Amiodipine enhances the protective activity of ethosuximide and valproate magnesium against pentylenetetrazol-induced seizures in mice European Neuropsychopharmacology. 7. DOI: 10.1016/S0924-977X(97)88901-8 |
0.469 |
|
| Show low-probability matches. |